2018 American Transplant Congress
Impact of Direct Acting Antiviral Agents (DAAs) for Hepatitis C Virus (HCV)-Induced Liver Diseases on Registration and Outcome on Waiting List (WL) for Liver Transplant (LT)
2d-generation DAAs have dramatically improved the management of patients with HCV, including patients with advanced diseases. In France, since 2013, DAA have been largely used,…2018 American Transplant Congress
Impact of Direct Antiviral Therapy for Hepatitis C on Acute Rejection and DSA Formation in Kidney Transplant Recipients
Cleveland Clinic, Cleveland, OH.
Background: Hepatitis C virus infection (HCV) has historically portended a poor outcome after kidney transplantation. With recent advent of direct antiviral agents (DAA), there has…2018 American Transplant Congress
Impact of Direct Acting Antivirals of Hepatitis C Virus Therapy on Tacrolimus Dosing Post-Liver Transplant
Michigan Medicine, Ann Arbor, MI.
Background: Direct acting antivirals (DAA) have transformed hepatitis C virus (HCV) management post-liver transplant (LT). As HCV clears, hepatic metabolism improves, resulting in decreased tacrolimus…2018 American Transplant Congress
Safety and Efficacy of Sofosbuvir-Based Direct-Acting Antiviral Agents in Kidney Transplant Recipients with HCV: A Systematic Review and Meta-Analysis
Background: Outcome data on sofosbuvir (SOF)-based therapy in patients with kidney transplantation (KTx) with hepatitis C virus infection are limited with individual studies having a…2018 American Transplant Congress
Private Insurance is Associated with Reduce Access to HCV Therapy after Liver Transplantation
Effective treatment for hepatitis C virus (HCV) infection has revolutionized post liver transplant (LTx) care. Administration of direct-acting antiviral agents (DAAs) after HCV+ LTx results…2018 American Transplant Congress
Elbasvir-Grazoprevir (Zepatier) is Effective and Safe for the Treatment of Chronic Hepatitis C (HCV) Genotype 1 Virus in the Post Kidney Transplant Patient
Objective: Limited real world data exists regarding the use of direct acting antivirals (DAA) for HCV viremia in renal transplant patients, particularly those with marked…2017 American Transplant Congress
Impact of Alemtuzumab Induction on Hepatitis C Treatment Outcomes Post-Renal Transplantation.
University of Maryland Medical Center, Baltimore, MD
BackgroundDirect-acting antiviral agents (DAAs) have improved treatment outcomes for Hepatitis C virus (HCV). Given high rates of treatment success with few side effects, eradication of…2017 American Transplant Congress
Effect of Hepatitis C (HCV) Treatment on Rejection Incidence and Severity in Post-Liver Transplant Patients.
Organ Transplant, Scripps Clinic, La Jolla, CA
Introduction: Hepatitis C remains an important source of morbidity and mortality post liver transplant. Little is known about the long term effects of direct acting…2017 American Transplant Congress
Use of Hepatitis C Infected Organs for Kidney Transplantation: A Medical Decision Analysis.
1Dalhousie University, Halifax, NS, Canada; 2University of Alberta, Edmonton, AB, Canada
Given that Hepatitis C (HCV) can be cured, organs from HCV+ deceased donors might be used in HCV- recipients if treatment at the time of…2017 American Transplant Congress
HCV Eradication with DAA Therapy Should Be Attempted Prior to Liver Transplantation and Does Not Impact HCC Recurrence.
University of Alberta, Edmonton, AB, Canada
Background: Recent advances in the direct-acting antiviral (DAA) treatment of HCV have lead to high rates of HCV eradication, even in patients with decompensated cirrhosis.…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 28
- Next Page »